JP2022516318A5 - - Google Patents

Info

Publication number
JP2022516318A5
JP2022516318A5 JP2021538996A JP2021538996A JP2022516318A5 JP 2022516318 A5 JP2022516318 A5 JP 2022516318A5 JP 2021538996 A JP2021538996 A JP 2021538996A JP 2021538996 A JP2021538996 A JP 2021538996A JP 2022516318 A5 JP2022516318 A5 JP 2022516318A5
Authority
JP
Japan
Prior art keywords
item
mir
lnp
copies
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021538996A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516318A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/012237 external-priority patent/WO2020142725A1/en
Publication of JP2022516318A publication Critical patent/JP2022516318A/ja
Publication of JP2022516318A5 publication Critical patent/JP2022516318A5/ja
Priority to JP2024143254A priority Critical patent/JP2024167285A/ja
Pending legal-status Critical Current

Links

JP2021538996A 2019-01-04 2020-01-03 カプセル化ポリヌクレオチド及び使用方法 Pending JP2022516318A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024143254A JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962788504P 2019-01-04 2019-01-04
US62/788,504 2019-01-04
US201962895135P 2019-09-03 2019-09-03
US62/895,135 2019-09-03
PCT/US2020/012237 WO2020142725A1 (en) 2019-01-04 2020-01-03 Encapsulated rna polynucleotides and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024143254A Division JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Publications (2)

Publication Number Publication Date
JP2022516318A JP2022516318A (ja) 2022-02-25
JP2022516318A5 true JP2022516318A5 (https=) 2023-01-19

Family

ID=71406664

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021538996A Pending JP2022516318A (ja) 2019-01-04 2020-01-03 カプセル化ポリヌクレオチド及び使用方法
JP2024143254A Pending JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024143254A Pending JP2024167285A (ja) 2019-01-04 2024-08-23 カプセル化ポリヌクレオチド及び使用方法

Country Status (13)

Country Link
US (1) US20220117902A1 (https=)
EP (1) EP3906039A4 (https=)
JP (2) JP2022516318A (https=)
KR (1) KR20210113260A (https=)
CN (1) CN113453699A (https=)
AU (1) AU2020204989A1 (https=)
BR (1) BR112021013155A2 (https=)
CA (1) CA3124524A1 (https=)
IL (1) IL284433A (https=)
MX (1) MX2021008146A (https=)
SG (1) SG11202107282VA (https=)
TW (1) TW202043480A (https=)
WO (1) WO2020142725A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240586T1 (hr) 2018-10-09 2024-07-19 The University Of British Columbia Sastavi i sustavi koji sadrže transfekcijske sposobne vezikle bez organskih otapala i deterdženta i s njim povezanim postupcima
BR112022000928A2 (pt) 2019-07-19 2022-03-08 Seneca Therapeutics Inc Terapia oncolítica do vírus seneca valley de segunda geração: composições e métodos da mesma
US20220267799A1 (en) * 2019-08-05 2022-08-25 Virogin Biotech Canada Ltd Genetically modified enterovirus vectors
EP4271389A4 (en) * 2020-12-29 2026-04-08 Rejuvenation Tech Inc COMPOSITIONS AND METHODS FOR ADMINISTRATING RNA
WO2022150485A1 (en) * 2021-01-06 2022-07-14 Oncorus, Inc. Encapsulated rna polynucleotides and methods of use
EP4281549A4 (en) * 2021-01-19 2025-05-07 Seneca Therapeutics, Inc. ONCOLYTIC THERAPY COMPOSITIONS CONTAINING SENECA VALLEY VIRUS AND METHODS THEREFOR
EP4297728A1 (en) * 2021-02-23 2024-01-03 Poseida Therapeutics, Inc. Compositions and methods for delivery of nucleic acids
EP4312942A4 (en) * 2021-03-31 2025-03-19 Rejuvenation Technologies Inc. Compositions and methods for delivery of RNA
JP2024534066A (ja) * 2021-08-17 2024-09-18 モナシュ ユニバーシティー 脂質ナノ粒子製剤
CA3234321A1 (en) * 2021-09-30 2023-04-06 Nof Corporation Lipid nanoparticles used to transport nucleic acids into lymphatic endothelium cells
CA3234320A1 (en) * 2021-09-30 2023-04-06 Nof Corporation Lipid nanoparticle used for delivering nucleic acid to brain tissue
CN113980915B (zh) * 2021-11-04 2023-07-07 江苏省人民医院（南京医科大学第一附属医院） 一种新型的表达cxcl10的复制型溶瘤腺病毒和应用
FR3129833B1 (fr) 2021-12-03 2024-09-06 Univ Claude Bernard Lyon Nanoparticules pour la liberation d’acides nucleiques
WO2023165583A1 (zh) * 2022-03-04 2023-09-07 益杰立科(上海)生物科技有限公司 靶向眼部细胞的递送系统和方法
US20260077037A1 (en) * 2022-07-04 2026-03-19 Bharat Biotech International Limited Cationic lipid based composition, formulation and use for nucleic acid vaccine delivery and preparation thereof
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用
EP4604928A1 (en) * 2022-10-21 2025-08-27 Georgia Tech Research Corporation Lymphatic endothelial cell-specific lipid nanoparticle and uses thereof
WO2024226779A1 (en) * 2023-04-26 2024-10-31 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations
KR20250042873A (ko) 2023-09-20 2025-03-28 한국과학기술연구원 종양 표적 리간드를 포함하는 지질나노입자, 이의 제조방법 및 이를 포함하는 약학 조성물
WO2025196641A1 (ru) * 2024-03-19 2025-09-25 Биоплатформ Гмбх Гибридные частицы, способ их получения и применение
WO2025230906A1 (en) * 2024-04-29 2025-11-06 Saliogen Therapeutics, Inc. Lipid nanoparticle (lnp) formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7638318B2 (en) * 2003-09-26 2009-12-29 Norvartis Ag Seneca Valley virus based compositions and methods for treating disease
EP1843773A4 (en) * 2005-01-17 2008-07-30 Viralytics Ltd METHOD AND COMPOSITION FOR TREATING NEOPLASIA
CA2609142C (en) * 2005-05-27 2016-02-09 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic gene vectors comprising mirna target sequences
US20100111873A1 (en) * 2007-02-20 2010-05-06 Russell Stephen J Treating cancer with viral nucleic acid
TW201021853A (en) * 2008-11-17 2010-06-16 Enzon Pharmaceuticals Inc Releasable cationic lipids for nucleic acids delivery systems
WO2013073480A1 (ja) * 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
EP2852380A4 (en) * 2012-05-23 2016-01-20 Univ Ohio State LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF
JP6396891B2 (ja) * 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
EP3247363A4 (en) * 2015-01-21 2018-10-03 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
KR20180136435A (ko) * 2016-01-27 2018-12-24 온코루스, 인크. 종양 살상형 바이러스 벡터 및 그의 용도
AU2017290828A1 (en) * 2016-06-30 2019-01-24 Virogin Biotech Canada Ltd Pseudotyped oncolytic viral delivery of therapeutic polypeptides
EP3597197A4 (en) * 2017-03-17 2021-01-06 National University Corporation Chiba University Novel technique for treating cancer using structurally-reinforced s-tud
US12037608B2 (en) * 2017-04-19 2024-07-16 The University Of Tokyo Genetically engineered coxsackievirus, and pharmaceutical composition
WO2018218137A1 (en) * 2017-05-25 2018-11-29 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
KR20200036873A (ko) * 2017-07-14 2020-04-07 온코루스, 인크. 캡슐화된 폴리뉴클레오티드 및 사용 방법

Similar Documents

Publication Publication Date Title
JP2022516318A5 (https=)
JP2024503623A5 (https=)
Liu et al. mRNA-based cancer therapeutics
Han et al. Nanomaterials for therapeutic RNA delivery
US11713336B2 (en) Peptides and nanoparticles for intracellular delivery of molecules
Fu et al. Recent progress in microRNA-based delivery systems for the treatment of human disease
Tyagi et al. Exploiting nanotechnology for the development of microRNA-based cancer therapeutics
JP2020530778A5 (https=)
JP2022507269A5 (https=)
JP2021522248A (ja) 粒子状製剤用の凍結保護剤
CN113453699A (zh) 包封的rna多核苷酸及使用方法
JP2023528300A5 (https=)
RU2020106730A (ru) Инкапсулированные полинуклеотиды и способы их применения
Cai et al. Synthetic circRNA therapeutics: innovations, strategies, and future horizons
JP2024503623A (ja) カプセル化ｒｎａポリヌクレオチド及び使用方法
Anand et al. Metabolic stability and targeted delivery of oligonucleotides: advancing RNA therapeutics beyond the liver
Zwolsman et al. Engineering lipid nanoparticles for mRNA immunotherapy
Tian et al. DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy
CN118556131A (zh) 用于蛋白质表达的mRNA及其模板
Begum et al. Advances in targeted gene delivery
EP3265132A1 (en) Nanoparticle conjugates and uses thereof
Yang et al. Advancing cancer treatment: in vivo delivery of therapeutic small noncoding RNAs
Zhang et al. Cellular functions and biomedical applications of circular RNAs: Cellular functions and biomedical applications of circular RNAs
Wang et al. Targeted gene delivery systems for T-cell engineering
Arenas et al. Opportunities of miRNAs in cancer therapeutics